Imugene Limited (IUGNF)
USD 0.03
(4.0%)
USD 0.03
(4.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 135.09 Million AUD | 175.19% |
| 2023 | 49.08 Million AUD | -3.13% |
| 2022 | 50.67 Million AUD | 97.43% |
| 2021 | 25.66 Million AUD | 72.5% |
| 2020 | 14.87 Million AUD | 20.1% |
| 2019 | 12.38 Million AUD | 114.32% |
| 2018 | 5.78 Million AUD | 56.8% |
| 2017 | 3.68 Million AUD | -13.64% |
| 2016 | 4.26 Million AUD | 47.99% |
| 2015 | 2.88 Million AUD | 115.94% |
| 2014 | 1.33 Million AUD | -23.2% |
| 2013 | 1.73 Million AUD | 23.95% |
| 2012 | 1.4 Million AUD | -25.67% |
| 2011 | 1.88 Million AUD | -11.07% |
| 2010 | 2.12 Million AUD | -23.01% |
| 2009 | 2.75 Million AUD | 7.7% |
| 2008 | 2.56 Million AUD | -15.84% |
| 2007 | 3.04 Million AUD | -3.49% |
| 2006 | 3.15 Million AUD | 25.44% |
| 2005 | 2.51 Million AUD | 2.94% |
| 2004 | 2.44 Million AUD | 0.53% |
| 2003 | 2.42 Million AUD | 640.41% |
| 2002 | 328 Thousand AUD | -87.28% |
| 2001 | 2.57 Million AUD | 158.58% |
| 2000 | -4.4 Million AUD | 10.24% |
| 1999 | -4.9 Million AUD | -8.52% |
| 1998 | -4.51 Million AUD | -424.34% |
| 1997 | 1.39 Million AUD | 59.93% |
| 1996 | 871 Thousand AUD | -6.84% |
| 1995 | 935 Thousand AUD | 22.06% |
| 1994 | 766 Thousand AUD | 192.37% |
| 1993 | 262 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 67.55 Million AUD | 0.0% |
| 2024 Q1 | 39.53 Million AUD | 34.55% |
| 2024 Q2 | 79.23 Million AUD | 100.39% |
| 2024 FY | 135.09 Million AUD | 175.19% |
| 2023 Q2 | 21.9 Million AUD | 93.13% |
| 2023 Q3 | 14.42 Million AUD | -34.13% |
| 2023 FY | 49.08 Million AUD | -3.13% |
| 2023 Q4 | 29.38 Million AUD | 103.66% |
| 2023 Q1 | 11.34 Million AUD | -62.38% |
| 2022 Q1 | 10.27 Million AUD | -33.81% |
| 2022 FY | 50.67 Million AUD | 97.43% |
| 2022 Q4 | 30.15 Million AUD | 97.95% |
| 2022 Q3 | 15.23 Million AUD | -25.78% |
| 2022 Q2 | 20.52 Million AUD | 99.69% |
| 2021 Q2 | 10.14 Million AUD | 100.29% |
| 2021 Q1 | 5.06 Million AUD | -33.59% |
| 2021 FY | 25.66 Million AUD | 72.5% |
| 2021 Q4 | 15.52 Million AUD | 98.0% |
| 2021 Q3 | 7.84 Million AUD | -22.67% |
| 2020 Q4 | 7.62 Million AUD | 98.89% |
| 2020 FY | 14.87 Million AUD | 20.1% |
| 2020 Q3 | 3.83 Million AUD | -47.17% |
| 2020 Q2 | 7.25 Million AUD | 99.52% |
| 2020 Q1 | 3.63 Million AUD | -48.04% |
| 2019 Q1 | 2.63 Million AUD | 49.67% |
| 2019 FY | 12.38 Million AUD | 114.32% |
| 2019 Q4 | 6.99 Million AUD | 98.6% |
| 2019 Q3 | 3.52 Million AUD | 33.9% |
| 2019 Q2 | 2.63 Million AUD | -0.0% |
| 2018 Q1 | 1.17 Million AUD | 64.39% |
| 2018 Q2 | 1.17 Million AUD | 0.0% |
| 2018 Q3 | 1.75 Million AUD | 49.52% |
| 2018 Q4 | 1.75 Million AUD | 0.0% |
| 2018 FY | 5.78 Million AUD | 56.8% |
| 2017 FY | 3.68 Million AUD | -13.64% |
| 2017 Q4 | 715.4 Thousand AUD | 0.0% |
| 2017 Q3 | 715.4 Thousand AUD | -37.11% |
| 2017 Q2 | 1.13 Million AUD | -0.0% |
| 2017 Q1 | 1.13 Million AUD | -12.73% |
| 2016 Q1 | 843.94 Thousand AUD | 9.14% |
| 2016 Q4 | 1.3 Million AUD | 0.0% |
| 2016 Q3 | 1.3 Million AUD | 54.45% |
| 2016 Q2 | 843.94 Thousand AUD | 0.0% |
| 2016 FY | 4.26 Million AUD | 47.99% |
| 2015 Q4 | 773.29 Thousand AUD | 0.0% |
| 2015 FY | 2.88 Million AUD | 115.94% |
| 2015 Q1 | 766.43 Thousand AUD | 35.01% |
| 2015 Q2 | 766.43 Thousand AUD | -0.0% |
| 2015 Q3 | 773.29 Thousand AUD | 0.89% |
| 2014 Q3 | 567.68 Thousand AUD | -25.25% |
| 2014 Q4 | 567.68 Thousand AUD | 0.0% |
| 2014 Q2 | 759.45 Thousand AUD | -0.0% |
| 2014 Q1 | 759.45 Thousand AUD | 194.41% |
| 2014 FY | 1.33 Million AUD | -23.2% |
| 2013 FY | 1.73 Million AUD | 23.95% |
| 2013 Q3 | 257.95 Thousand AUD | 0.0% |
| 2013 Q4 | 257.95 Thousand AUD | 0.0% |
| 2012 FY | 1.4 Million AUD | -25.67% |
| 2011 FY | 1.88 Million AUD | -11.07% |
| 2010 FY | 2.12 Million AUD | -23.01% |
| 2009 FY | 2.75 Million AUD | 7.7% |
| 2008 FY | 2.56 Million AUD | -15.84% |
| 2007 FY | 3.04 Million AUD | -3.49% |
| 2006 FY | 3.15 Million AUD | 25.44% |
| 2005 FY | 2.51 Million AUD | 2.94% |
| 2004 FY | 2.44 Million AUD | 0.53% |
| 2003 FY | 2.42 Million AUD | 640.41% |
| 2002 FY | 328 Thousand AUD | -87.28% |
| 2001 FY | 2.57 Million AUD | 158.58% |
| 2000 FY | -4.4 Million AUD | 10.24% |
| 1999 FY | -4.9 Million AUD | -8.52% |
| 1998 FY | -4.51 Million AUD | -424.34% |
| 1997 FY | 1.39 Million AUD | 59.93% |
| 1996 FY | 871 Thousand AUD | -6.84% |
| 1995 FY | 935 Thousand AUD | 22.06% |
| 1994 FY | 766 Thousand AUD | 192.37% |
| 1993 FY | 262 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -55.662% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2646.914% |
| SQZ Biotechnologies Company | 85.61 Million USD | -57.781% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -357.114% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -262.605% |
| Mesoblast Limited | 5.9 Million USD | -2188.899% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -8894.669% |
| Genus plc | 147.7 Million USD | 8.537% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1438.754% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -9969.796% |
| Marizyme, Inc. | 19.23 Million USD | -602.142% |
| ContraFect Corporation | 56.88 Million USD | -137.464% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1519.989% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -2964.207% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -9035.463% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -4532.372% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -4741.346% |
| MultiCell Technologies, Inc. | 567.42 USD | -23807810.895% |
| Accustem Sciences Inc. | 3.74 Million USD | -3505.866% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -57.183% |
| EV Biologics, Inc. | 531.96 Thousand USD | -25294.83% |
| Q BioMed Inc. | 3.43 Million USD | -3830.913% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -446.595% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -34577.269% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -5041.378% |
| Biomind Labs Inc. | 994.18 Thousand USD | -13488.141% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 40.09% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1910.874% |
| Skye Bioscience, Inc. | 13.54 Million USD | -897.161% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -6493.963% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 540463.392% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2579.287% |
| IMV Inc. | 37.7 Million USD | -258.244% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -743.778% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -7261.518% |
| GB Sciences, Inc. | 1.42 Million USD | -9410.031% |
| Alpha Cognition Inc. | 9.7 Million USD | -1291.885% |
| HST Global, Inc. | 140.9 Thousand USD | -95772.347% |
| CSL Limited | 3.44 Billion USD | 96.083% |
| Halberd Corporation | 74.84 Thousand USD | -180401.387% |
| Enzolytics Inc. | 2.17 Million USD | -6098.23% |
| Resverlogix Corp. | 12.71 Million USD | -962.703% |
| Affymax, Inc. | 39.38 Million USD | -242.992% |
| SYBLEU INC | 160.87 Thousand USD | -83872.033% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -3600.402% |
| argenx SE | 1.53 Billion USD | 91.191% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -135.186% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -12839.736% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -8453.545% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -3867.45% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1747.961% |
| Zenith Capital Corp. | 8.94 Million USD | -1410.576% |
| Genscript Biotech Corporation | 825.34 Million USD | 83.632% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -775348.298% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -5401.972% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -78666.04% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -36.002% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -7577.021% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -6750.331% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -7145.925% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1143.129% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -6932.663% |
| BioStem Technologies, Inc. | 22.97 Million USD | -487.996% |
| ONE Bio Corp. | 6.44 Million USD | -1996.417% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -74336.371% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -10015.899% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -11909.036% |
| Agentix Corp. | 1.37 Million USD | -9748.023% |
| LadRx Corporation | 3.81 Million USD | -3444.026% |
| Cell Source, Inc. | 4.32 Million USD | -3023.238% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -32414.483% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -14527.979% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -14527.979% |
| NovAccess Global Inc. | 2.46 Million USD | -5376.447% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -5517.237% |
| Itoco Inc. | 919.14 Thousand USD | -14597.479% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -3087.297% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -11972.462% |
| Kadimastem Ltd | 2.41 Million USD | -5505.169% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -51515.372% |
| CytoDyn Inc. | 18.05 Million USD | -648.094% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -536635.063% |
| Mobile Lads Corp. | 554.54 Thousand USD | -24260.621% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -61283.168% |
| Qrons Inc. | 643.67 Thousand USD | -20887.366% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -9414.834% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -5958.214% |
| Rebus Holdings, Inc. | 664 Thousand USD | -20245.007% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -7337.613% |
| International Stem Cell Corporation | 5.27 Million USD | -2462.907% |
| Bioxytran, Inc. | 3.82 Million USD | -3436.274% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -256521.8% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -663965.516% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -272.5% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -8249.249% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -18258.851% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -4242.361% |
| Neutra Corp. | 243.82 Thousand USD | -55305.748% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -673.849% |
| PureTech Health plc | 144.59 Million USD | 6.574% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -559.305% |
| IXICO plc | 4.7 Million USD | -2769.999% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1435.647% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -14.729% |
| CSL Limited | 3.89 Billion USD | 96.53% |
| Cellectis S.A. | 97.32 Million USD | -38.811% |